BML-277 10mg 10mg | Purity Not Available
Adooq Bioscience
BML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageBML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageLH 846 is a selective inhibitor of casein kinase (CK) 1?? (IC50 values are 290 nM, 1.3 ??M and 2.5 ??M for CK1??, ?? and ??)
More Information Supplier PageLH 846 is a selective inhibitor of casein kinase (CK) 1?? (IC50 values are 290 nM, 1.3 ??M and 2.5 ??M for CK1??, ?? and ??)
More Information Supplier PageLH 846 is a selective inhibitor of casein kinase (CK) 1?? (IC50 values are 290 nM, 1.3 ??M and 2.5 ??M for CK1??, ?? and ??)
More Information Supplier PageLH 846 is a selective inhibitor of casein kinase (CK) 1?? (IC50 values are 290 nM, 1.3 ??M and 2.5 ??M for CK1??, ?? and ??)
More Information Supplier PagePP1 Analog II, 1NM-PP1 is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.
More Information Supplier PagePP1 Analog II, 1NM-PP1 is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.
More Information Supplier PageBML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageGLYX-13 is a selective weak partial agonist of the glycine site of the NMDA receptor (IA ?? 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression.
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 ??M, 0.48 ??M and 0.18 ??M; does not inhibit BIR3 domain and BID
More Information Supplier Page